Cambiar Investors LLC Sells 164,965 Shares of HealthEquity, Inc. (NASDAQ:HQY)

Cambiar Investors LLC cut its holdings in shares of HealthEquity, Inc. (NASDAQ:HQY) by 87.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 23,780 shares of the company’s stock after selling 164,965 shares during the quarter. Cambiar Investors LLC’s holdings in HealthEquity were worth $2,282,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in HQY. Wasatch Advisors LP increased its holdings in shares of HealthEquity by 6.6% during the third quarter. Wasatch Advisors LP now owns 7,758,890 shares of the company’s stock worth $635,065,000 after purchasing an additional 483,269 shares during the period. Vaughan Nelson Investment Management L.P. increased its holdings in shares of HealthEquity by 36.7% during the third quarter. Vaughan Nelson Investment Management L.P. now owns 843,423 shares of the company’s stock worth $69,034,000 after purchasing an additional 226,563 shares during the period. Barclays PLC increased its stake in HealthEquity by 209.3% in the third quarter. Barclays PLC now owns 166,492 shares of the company’s stock valued at $13,628,000 after acquiring an additional 112,667 shares during the last quarter. Thrivent Financial for Lutherans increased its stake in HealthEquity by 33.3% in the third quarter. Thrivent Financial for Lutherans now owns 293,624 shares of the company’s stock valued at $24,033,000 after acquiring an additional 73,404 shares during the last quarter. Finally, B. Metzler seel. Sohn & Co. Holding AG bought a new position in HealthEquity in the third quarter valued at approximately $5,675,000. 99.55% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on HQY. Bank of America lifted their price objective on shares of HealthEquity from $100.00 to $120.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. The Goldman Sachs Group began coverage on shares of HealthEquity in a research note on Friday, November 15th. They issued a “neutral” rating and a $108.00 price objective on the stock. JMP Securities lifted their price objective on shares of HealthEquity from $105.00 to $107.00 and gave the company a “market outperform” rating in a research note on Tuesday, December 10th. Barrington Research lifted their price objective on shares of HealthEquity from $105.00 to $120.00 and gave the company an “outperform” rating in a research note on Monday, December 2nd. Finally, Mizuho began coverage on shares of HealthEquity in a research note on Wednesday, December 4th. They issued an “outperform” rating and a $126.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $110.71.

HealthEquity Price Performance

Shares of NASDAQ:HQY opened at $112.15 on Tuesday. The firm has a market cap of $9.72 billion, a PE ratio of 102.89, a price-to-earnings-growth ratio of 1.61 and a beta of 0.55. The firm’s fifty day moving average is $101.18 and its 200-day moving average is $89.98. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.20 and a current ratio of 3.20. HealthEquity, Inc. has a 52 week low of $65.01 and a 52 week high of $113.61.

HealthEquity (NASDAQ:HQY) last issued its quarterly earnings results on Monday, December 9th. The company reported $0.59 EPS for the quarter, missing analysts’ consensus estimates of $0.71 by ($0.12). HealthEquity had a return on equity of 9.70% and a net margin of 8.41%. During the same quarter last year, the business posted $0.40 EPS. Sell-side analysts predict that HealthEquity, Inc. will post 2.32 earnings per share for the current year.

Insider Activity at HealthEquity

In related news, Director Stuart B. Parker sold 25,000 shares of the business’s stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $96.72, for a total value of $2,418,000.00. Following the transaction, the director now owns 19,061 shares in the company, valued at $1,843,579.92. The trade was a 56.74 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Robert W. Selander sold 8,250 shares of the business’s stock in a transaction on Monday, December 9th. The shares were sold at an average price of $101.56, for a total transaction of $837,870.00. Following the completion of the transaction, the director now owns 66,469 shares in the company, valued at approximately $6,750,591.64. The trade was a 11.04 % decrease in their position. The disclosure for this sale can be found here. 2.20% of the stock is owned by company insiders.

About HealthEquity

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.